Dyax Corporation (DYAX) Q2 2012 Earnings Call July 19, 2012, 5:00 p.m. ET Executives Gustav Christiansen – President, CEO Rick Berard – VP Commercial Burt Adelman – Chief Medical Officer Ivana Magovčević-Liebisch - EVP, Corporate Development and General Counsel George Miguasky - EVP, CFO. Analysts Joseph Schwartz – Leerink Swann LLC Phil Nadeau - Cowen and Company Serge Boulanger – Needham and Company Presentation Operator
Previous Statements by DYAX
» Dyax's CEO Presents at Deutsche Bank AG Health Care Conference (Transcript)
» Dyax Corporation CEO Discusses 3Q 2010 Results - Earnings Call Transcript
» Dyax Corp. Q2 2010 Earnings Call Transcript
» Dyax Corporation Q1 2010 Earnings Call Transcript
Thank you, Jen. Good evening everyone and welcome to Dyax Corp.’s second quarter 2012 earnings call. My remarks today will provide you with highlights on the second quarter, and a review of our key value drivers, KALBITOR angioedema franchise, as well as the Licensing and Funding Research Program.We are pleased to report another strong quarter for our KALBITOR business, marking the ninth quarter in a row of steady, consistent revenue growth. This is based on solid execution of our strategy to provide patients with premiere services and support. We will go into more detailed account of the KALBITOR business momentarily, but I want to mention a few key metrics and achievements we had this past quarter. First, KALBITOR sales for the second quarter were $9.2 million, up 14% from the first quarter of 2012. Second, patients treated with KALBITOR increased to 518, up 12% from the first quarter of 2012. This continued positive momentum is a result of delivering first class services and support to the entire HAE community, including patients, advocates and healthcare professionals. We have launched several new programs in the last quarter, designed to identify and attract new patients, which together with our entire suite of offerings positions Dyax for continued growth in the KALBITOR business. Along with the developing the HAE market, we are also leveraging our knowledge of the plasma kallikrein pathway to ultimately diagnose and treat other angioedema states. Our second pillar, the LFRP, continues to be a near- and long-term value driver for Dyax. It already provides us with approximately $15 million in revenues annually, and has significant potential, through its broad and maturing pipeline of clinical candidates, addressing large therapeutic markets. For more detail on these key business areas, I’ll now turn the call over to our executive management team. First, Rick Berard, Vice President, Commercial, will discuss our ongoing marketing efforts for KALBITOR in the U.S. Dr. Burt Adelman, Chief Medical Officer, will discuss our resurging initiatives in the angioedema franchise. Dr. Ivana Magovčević-Liebisch, Chief Business Officer, will discuss our global expansion efforts for KALBITOR, as well as the LFRP. And finally, George Miguasky, Chief Financial Officer, will present our financial highlights and financial guidance. Following these updates, I will provide concluding remarks, then open the lines for Q&A. At this time, I will turn the call over to Rick, who will review the progress of KALBITOR in the U.S.
Rick BerardThank you, Gustav. Good evening. We built on the momentum from the first quarter by focusing on three key objectives: patient identification, patient treatment and patient re-treatment. We remain dedicated to providing patients and healthcare providers with unparalleled resources to build awareness, treat and manage acute attacks of HAE. The results of these efforts have been meaningful. In the second quarter, KALBITOR net sales were 9.2 million, an increase of 14% quarter-over-quarter, reflecting steady increases across multiple patient metrics. As of June 30 th, 518 patients were treated with KALBITOR, an increase of 12% from the first quarter; 59% of patients with drug are now treating. The vast majority of these patients have already re-treated with KALBITOR, and the KALBITOR treatment rate remains between six to nine attacks on a forecasted, annualized basis, and KALBITOR patients receiving patient-supplied drug, or PSD, are showing treatment rates at the top or above this range. This strong, consistent growth is a result of our focused marketing plan, an expanding suite of support and service programs which continues to distinguish Dyax as a leader in the treatment of HAE. One program that clearly differentiates Dyax in the HAE marketplace is the KALBITOR home infusion services. This program provides patients with a convenient, monitored treatment option in the comfort of their home by a qualified and knowledgeable home infusion nurse, available 24 hours a day, seven days a week. Both patients and physicians increasingly recognize the value of this service, with most new patients electing this option. Read the rest of this transcript for free on seekingalpha.com